Cancer stem cells in many types of hematologic malignancies and solid tumors are believed to be a cell population required for cancer initiation, and must be targeted for effective treatment of the diseases [@R1]--[@R7]; however, the direct supporting evidence is still lacking. The challenge includes identification of differences between cancer stem cells and their normal stem cell counterparts, and demonstration of complete control of cancer by targeting these stem cells. Success of an anti-stem cell strategy relies on complete inhibition of function of a gene required for the maintenance of cancer stem cells but not normal stem cells. A number of genes have been found to promote or inhibit cancer cell proliferation, but they also play similar roles in regulating normal stem cells. Examples include pathways involved in signaling through Wnt/β-catenin, Hedgehog and Notch [@R3],[@R4],[@R8]--[@R11], Bim-1 [@R12],[@R13], p53 [@R8], p16 ^INK4a^ [@R14], p19^ARF^ [@R15], etc. The role of *Pten* in the inhibition of cancer stem cells of acute myeloid leukemia (AML) and in the maintenance of normal HSCs is unique, and provides an example that distinguishes AML stem cells from normal HSCs, although *Pten* has an effect on normal HSCs [@R16]. Because cancer stem cells express markers similar to those on normal stem cells [@R17],[@R18], the major difference between them should be related to the cancer-initiating genetic changes such as acquiring an oncogene or accumulating a DNA mutation. It is reasonable to hypothesize that these genetic changes cause aberrant expression of genes, consequently turning a normal stem cell into a cancer stem cell. It is essential to identify genes that are functionally required by cancer stem cells but not by normal stem cell counterparts. Some clues for identifying genes that play roles in cancer stem cells could come from studies of normal stem cell counterparts and different lineages of cancer cells [@R19]--[@R22]. It is reasonable to think that biological features of cancer stem cells are reflected by the deference in gene expression between cancer and normal stem cells. The list of aberrantly expressed genes could be huge, and it is critical to identify key genes or pathways that are required for initiating and maintaining cancer stem cells and can be used as targets for inhibiting these cells.

We have tested our hypothesis using BCR-ABL-induced CML as a disease model system, because CML is a stem cell disease and we have previously identified LSCs for CML in mice [@R23]. In addition, CML stem cells are insensitive to BCR-ABL kinase inhibitors [@R24],[@R25], calling for the development of new therapeutic strategies. Here we identify *Alox5* as a key gene that regulates the function of LSCs but not normal HSCs in mice. *Alox5* has been shown to be involved in numerous physiological and pathological processes, including oxidative stress response, inflammation, and cancer [@R26]--[@R33]. Here we also show that *Alox5* deficiency or inhibition of the function of this gene completely prevent the initiation of BCR-ABL-induced CML.

Results {#S1}
=======

*Alox5* is essential for the induction of CML by BCR-ABL {#S2}
--------------------------------------------------------

LSCs in CML are insensitive to BCR-ABL kinase inhibitors [@R24], and we believe that this insensitivity would correspond to unresponsiveness of some genes to the kinase inhibitors. To identify genes that are regulated by BCR-ABL in LSCs, we used the bone marrow transplantation (BMT) mouse model of CML as an assay system, in which bone marrow cells from donor mice pre-treated with 5-fluorouracil (5-FU) and transduced with BCR-ABL result in development of CML in recipient mice [@R34]. We transduced bone marrow cells from C57BL/6 (B6) mice with retrovirus containing BCR-ABL/GFP or GFP alone under conditions for the induction of CML, followed by transplantation of the transduced cells into B6 recipient mice. Some mice were treated with the BCR-ABL kinase inhibitor imatinib to allow identification of genes that were altered by BCR-ABL in LSCs, but this alteration was not restored by inhibition of BCR-ABL kinase activity with imatinib. This approach to identifying pathways that are activated by BCR-ABL but are insensitive to inhibition by imatinib is based on our previous observation that BCR-ABL kinase activity does not relate to all signaling pathways activated by BCR-ABL [@R23]. 14 days after BMT, bone marrow cells were isolated and subsequently sorted by FACS for LSCs (GFP^+^Lin^−^c-Kit^+^Sca-1^+^) [@R23]. Total RNA was isolated from these BCR-ABL-expressing LSCs or from the GFP^+^Lin^−^c-Kit^+^Sca-1^+^ cells that only expressed GFP, and DNA microarray analysis was carried out to compare gene expression between BCR-ABL-expressing and non-BCR-ABL-expressing Lin^−^c-Kit^+^Sca-1^+^ cells. The *Alox5* gene was up-regulated and this up-regulation was not abolished by imatinib treatment ([Fig. 1a](#F1){ref-type="fig"}). There were several genes that were also up-regulated by BCR-ABL and not changed in expression following imatinib treatment ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}). The up-regulation of *Alox5* by BCR-ABL in LSCs was confirmed by RT-PCR ([Fig. 1b](#F1){ref-type="fig"}). To further demonstrate the regulation of *Alox5* by BCR-ABL, we tested whether BCR-ABL up-regulates Alox5 function by measuring levels of leukotriene B4 (LTB4), which is synthesized and metabolized through the 5-LO pathway, in peripheral blood of the transplanted mice. Plasma level of LTB4 was increased in CML mice ([Fig. 1c](#F1){ref-type="fig"})

Next, we studied the role of *Alox5* in regulation of LSC function using *Alox5* homozygous knockout (*Alox5^−/−^*) mice. Wild type or *Alox5^−/−^* donor bone marrow cells in B6 background were used to induce CML. We first investigated whether *Alox5* is required for the induction of CML by BCR-ABL. Recipients of *BCR-ABL*-transduced bone marrow cells from 5-FU-treated wild type donor mice developed and died of CML within 4 weeks, whereas recipients of *BCR-ABL*-transduced bone marrow cells from *Alox5^−/−^* donor mice were resistant to the induction of CML ([Fig. 1d](#F1){ref-type="fig"}). This defective disease phenotype correlated with much less severe infiltration of myeloid leukemia cells in the lung and spleen ([Fig. 1e, f](#F1){ref-type="fig"}). In addition, FACS analysis of CML cells in peripheral blood and bone marrow showed that Gr-1^+^ myeloid leukemia cells grew initially, reached a peak after 2 weeks, then started to decline, and eventually disappeared after 7 weeks in peripheral blood and bone marrow of recipients receiving BCR-ABL-transduced *Alox5^−/−^* donor bone marrow cells ([Figs. 1 g , h](#F1){ref-type="fig"}). *Alox5* deficiency mainly affected growth of BCR-ABL-expressing (GFP^+^) but not non-BCR-ABL-expressing (GFP^−^) donor bone marrow cells ([Fig. 1h](#F1){ref-type="fig"}), suggesting that Alox5 signaling is much more critical for the function of LSCs but not normal HSCs. Together, these results demonstrate that *Alox5* pathway is essential for the induction of CML by BCR-ABL.

*Alox5* transgene rescues defective CML {#S3}
---------------------------------------

To further confirm the role of *Alox5* in CML development, we co-expressed *BCR-ABL* and *Alox5* in *Alox5^−/−^* and wild type bone marrow cells, respectively, by retroviral transduction, followed by transplantation of the transduced cells into recipient mice. The *BCR-ABL*-IRES-*Alox5*-pMSCV construct expressed BCR-ABL and 5-LO in 293T cells ([Fig. 2a](#F2){ref-type="fig"}), and induced LTB4 production in mice ([Fig. 2b](#F2){ref-type="fig"}). In contrast to no CML induction by BCR-ABL in the absence of *Alox5* ([Fig. 1](#F1){ref-type="fig"}), ectopically expressed *Alox5* in *Alox5^−/−^* bone marrow cells rescued defective CML phenotype, and all mice receiving the *BCR-ABL*-IRES-*Alox5*-pMSCV transduced *Alox5^−/−^* bone marrow cells died ([Fig. 2c](#F2){ref-type="fig"}). In this experiment, we included the control mice that received BCR-ABL transduced *Alox5^−/−^* bone marrow cells as shown in [Fig. 1](#F1){ref-type="fig"}, and all these mice survived (data not shown). FACS analysis ([Fig. 2d](#F2){ref-type="fig"}) and peripheral blood smears ([Fig. 2e](#F2){ref-type="fig"}) showed the development of typical CML after the expression of the rescue gene *Alox5*, consistent with the severe infiltration of myeloid leukemia cells in the lung and spleen ([Figs. 2f](#F2){ref-type="fig"}). The mice receiving the *BCR-ABL*-IRES-*Alox5*-pMSCV transduced wild type bone marrow cells died faster than those receiving the *BCR-ABL*-IRES-*Alox5*-pMSCV transduced *Alox5^−/−^* bone marrow cells ([Fig. 2c](#F2){ref-type="fig"}), correlating with more myeloid cells in peripheral blood ([Fig. 2d, e](#F2){ref-type="fig"}) and more severe infiltration of myeloid leukemia cells in the lung and spleen ([Fig. 2f](#F2){ref-type="fig"}). The results from this rescue experiment definitively confirmed that *Alox5* plays a critical role in CML development.

*Alox5* deficiency impairs the function of LSCs {#S4}
-----------------------------------------------

The eventual disappearance of myeloid leukemia cells in CML mice in the absence of *Alox5* ([Fig. 1h](#F1){ref-type="fig"}) prompted us to examine whether *Alox5* is required for self-renewal of LSCs. A biological assay for LSCs is to examine their ability to transfer disease to secondary recipient mice [@R17],[@R18]. We transferred bone marrow cells from primary recipients of *BCR-ABL*-transduced wild type or *Alox5^−/−^* donor bone marrow cells to secondary recipient mice. *BCR-ABL*-expressing wild type bone marrow cells transferred lethal CML, whereas *BCR-ABL*-expressing *Alox5^−/−^* bone marrow cells failed to induce CML in secondary recipient mice ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}). This result suggests that *Alox5* deficiency causes the impairment of the function of LSCs.

The impaired CML development in the absence of *Alox5* could be caused by decreased number of LSCs. To test this hypothesis, we quantified LSCs (GFP^+^Lin^−^c-Kit^+^Sca-1^+^) and normal HSCs (GFP^−^Lin^−^c-Kit^+^Sca-1^+^) in bone marrow and the spleens of CML mice at day 14 and day 18 after the induction of CML by BCR-ABL. At day 14, *Alox5* deficiency did not cause a reduction of LSCs in bone marrow and the spleens, but did so in bone marrow not in the spleens at day 18, as compared to LSCs in wild type CML mice ([Fig. 3a](#F3){ref-type="fig"}). In the spleen of these mice, the number of *Alox5^−/−^* LSCs at day 18 was similar to that of wild type LSCs ([Fig. 3a](#F3){ref-type="fig"}), indicating that the reduction of LSCs in bone marrow was not due to the migration of bone marrow LSCs to the spleens but due to an intrinsic defect caused by *Alox5* deficiency in LSCs. *Alox5* deficiency did not cause a significant reduction of normal HSCs (GFP^−^) in bone marrow and the spleens of the same animals ([Fig. 3a](#F3){ref-type="fig"}), suggesting that *Alox5* is functionally required by LSCs but not by normal HSCs. In addition, we did not observe a homing defect of HSCs lacking *Alox5* ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}), which could cause the impaired CML development ([Fig. 1](#F1){ref-type="fig"}). Furthermore, *Alox5* deficiency did not appear to cause a homing defect on LSCs, as the total number of *Alox5^−/−^* LSCs was not lower than that of wild type LSCs at day 14 after the induction of CML by BCR-ABL ([Fig. 3a](#F3){ref-type="fig"}).

Engraftment of donor bone marrow cells in lethally irradiated recipient mice reflects stem cell function. *Alox5* deficiency could cause a decreased engraftment of LSCs, leading to a decrease in LSCs. To test this idea, LSCs were sorted by FACS from bone marrow of CML induced by transplanting BCR-ABL-transduced wild type (CD45.1) or *Alox5^−/−^* (CD45.2) donor bone marrow cells. The sorted wild type and *Alox5^−/−^* LSCs were 1:1 mixed, followed by transplantation into lethally irradiated recipient mice. At day 14 or 25 after transplantation, more than 70% or 90% of GFP^+^Gr-1^+^ cells in peripheral blood of the mice were wild type (CD45.1^+^) leukemia cells, and all these mice developed CML and died ([Fig. 3b](#F3){ref-type="fig"}). Total wild type and *Alox5^−/−^* bone marrow cells that were not sorted by FACS were also 1:1 mixed, followed by transplantation into lethally irradiated recipient mice. At 40 day after BMT, more than 80% of GFP^+^Gr-1^+^ cells in peripheral blood were wild type (CD45.1^+^) leukemia cells, and all these mice died of CML ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}). To further compare biological function between wild type and *Alox5^−/−^* LSCs, *BCR-ABL*-transduced wild type or *Alox5^−/−^* bone marrow cells were sorted by FACS for Lin^−^c-Kit^+^Sca-1^+^ cells, and equal number of the sorted wild type or *Alox5^−/−^* cells were transplanted into each lethally irradiated recipient mouse. At day 14 after transplantation, GFP^+^Gr-1^+^ cells were detected in peripheral blood of recipient mice receiving *BCR-ABL*-transduced wild type bone marrow cells but barely in peripheral blood of mice receiving *BCR-ABL*-transduced *Alox5^−/−^* bone marrow cells ([Fig. 3c](#F3){ref-type="fig"}). By day 50 after transplantation, all mice receiving *BCR-ABL*-transduced sorted wild type bone marrow cells died of CML, whereas all mice receiving the transduced sorted *Alox5^−/−^* bone marrow cells survived ([Fig. 3c](#F3){ref-type="fig"}). These results indicated that *Alox5* deficiency caused impairment of the function of LSCs, presumably leading to reduced production of leukemia progenitor cells over time. This assumption was consistent with our finding that at day 20 after the induction of CML by BCR-ABL, similar numbers of GFP^+^ CMP (common myeloid progenitor), GMP (granulocyte-macrophage progenitor), and MEP (megakaryocyte-erythroid progenitor) cells were detected in bone marrow of mice receiving *BCR-ABL*-transduced *Alox5^−/−^* donor bone marrow cells ([Fig. 3d](#F3){ref-type="fig"}), and at day 45 the number of these cells were much less ([Fig. 3d](#F3){ref-type="fig"}). By contrast, *Alox5^−/−^* deficiency did not cause a reduction of non-BCR-ABL-expressing myeloid progenitor cells in the same animals ([Fig. 3d](#F3){ref-type="fig"}), providing an indirect evidence that *Alox5* deficiency only causes a functional defect in LSCs without affecting normal HSCs. The conclusion that *Alox5* deficiency does not cause a functional defect in normal HSCs was further confirmed by comparing the engraftment of wild type (CD45.1) and *Alox5^−/−^* (CD45.2) bone marrow cells by injecting the same number of each type of bone marrow cells into lethally irradiated recipient mice. At 30 day after BMT, the percentage of wild type or *Alox5^−/−^* bone marrow cells was similar ([Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}). A control experiment showed that after lethal irradiation, 100 % of cells in peripheral blood of recipient mice were donor-derived when assayed at day 30 after BMT (data not shown), allowing the direct analysis of CD45.1 or CD45.2 cells to reflect the donor-derived wild type (CD45.1) and *Alox5^−/−^* (CD45.2) bone marrow cells in the same animal.

*Alox5* deficiency affects differentiation, cell division and survival of LT-LSCs {#S5}
---------------------------------------------------------------------------------

*Alox5* deficiency caused the impairment of the function of LSCs ([Fig. 3](#F3){ref-type="fig"}), and these cells were Lin^−^c-Kit^+^Sca-1^+^ phenotypically, containing long-term (LT) HSCs, short-term (ST) HSCs, and multipotent progenitor (MPP) cells. We further investigated which of these cell populations is affected by *Alox5* deficiency. *BCR-ABL*-transduced *Alox5^−/−^* bone marrow cells were transplanted into recipient mice to induce CML, and bone marrow cells from these mice were analyzed by FACS for the percentages of total HSCs (Lin^−^c-Kit^+^Sca-1^+^), LT-HSCs (Lin^−^c-Kit^+^Sca-1^+^CD34^−^), and ST-HSCs /MPP cells (Lin^−^c-Kit^+^Sca-1^+^CD34^+^). At day 20 after the induction of CML by BCR-ABL, the percentage or total number of bone marrow LT-LSCs (GFP^+^Lin^−^c-Kit^+^Sca-1^+^CD34^−^) was about 1/2 of those of ST-LSCs/MPP cells (GFP^+^Lin^−^c-Kit^+^Sca-1^+^CD34^+^) ([Fig. 4a](#F4){ref-type="fig"}). However, at day 90, the percentage or total number of LT-LSCs was about 8 fold higher than that of ST-LSCs/MPP cells ([Fig. 4a](#F4){ref-type="fig"}). These results suggest that *Alox5* deficiency blocks differentiation of LT-LSCs, preventing these cells from developing CML. In these mice, the percentage of GFP^−^ LT-HSCs was much lower than that of GFP^−^ ST-HSCs/MPP cells ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}), demonstrating that *Alox5* deficiency did not similarly affect differentiation of normal LT-HSCs. Although loss of *Alox5* caused a relative high percentage of LT-LSCs than that of ST-LSCs/MPP cells, the total number of LT-LSCs declined with time ([Fig. 4a](#F4){ref-type="fig"}), suggesting that *Alox5* deficiency caused a gradual depletion of LSCs.

The effect of *Alox5* deficiency on LSCs was further demonstrated in experiments showing that *Alox5* function was inhibited by a selective 5-LO inhibitor Zileuton [@R35]. *BCR-ABL*-transduced wild type bone marrow cells were transplanted into recipient mice to induce CML, and LSCs in bone marrow of these mice treated with Zileuton (300 mg/kg of body weight, twice a day) were analyzed by FACS at days 20 and 90 after the induction of CML by BCR-ABL. As the treatment went on, the ratio between the percentage of LT-LSCs and that of ST-LSCs/MPP cells became increasing ([Fig. 4b](#F4){ref-type="fig"}), suggesting a blockade of differentiation of LT-LSCs. Zileuton treatment did not similarly affect differentiation of GFP^−^ LT-HSCs in the same animals ([Fig. 4b](#F4){ref-type="fig"}), demonstrating that inhibition of 5-LO did not suppress normal HSCs. These findings were consistent with those from the studies using *Alox5^−/−^* mice ([Fig. 4a](#F4){ref-type="fig"}). No suppression of normal HSCs was further demonstrated in placebo- or Zileuton-treated mice receiving wild type donor bone marrow cells transduced with MSCV-IRES-GFP retrovirus. At day 14 after BMT, the numbers of GFP^+^Lin^−^c-Kit^+^Sca-1^+^ cells in bone marrow of placebo- and Zileuton-treated mice were compared. Zileuton treatment did not result in a reduction of GFP^+^Lin^−^c-Kit^+^Sca-1^+^ cells in bone marrow and the spleens of the mice ([Fig. 4c](#F4){ref-type="fig"}).

The blockade of LT-LSC differentiation was correlated with biological and molecular changes in LSCs. Cell cycle analysis of LSCs in bone marrow of CML mice showed that there was higher percentage of LT-LSCs in the S+G2M phase of the cell cycle in mice receiving *BCR-ABL*-transduced *Alox5^−/−^* bone marrow cells than in mice receiving *BCR-ABL*-transduced wild type bone marrow cells ([Fig. 4d](#F4){ref-type="fig"}); however, the percentages of LT-LSCs and ST-LSCs/MPPs in the S+G2M phase of the cell cycle were similar ([Fig. 4d](#F4){ref-type="fig"}), suggesting that this differentiation blockade caused a compensatory response of *Alox5* deficient LSCs to the shortage of downstream cell lineages. However, the higher percentage of LT-LSCs in the S+G2M phase of the cell cycle in the absence of *Alox5* may also be explained by asymmetric cell division of LT-LSCs. In addition, *Alox5* deficiency caused slightly increased apoptosis of LSCs (p\> 0.05) ([Fig. 4e](#F4){ref-type="fig"}), but the apoptotic ratio between ST-LSCs/MPPs and LT-LSCs in the absence of *Alox5* was similar to that in the presence of *Alox5* ([Supplementary Fig. 7](#SD1){ref-type="supplementary-material"}). To study the underlying mechanism for the defective function of LSCs at molecular level, we examined the expressive levels of three regulatory genes of hematopoiesis, β-catenin, GATA-1 and FOG-1 [@R9],[@R36],[@R37]. We found that the defective function of LSCs in the absence of *Alox5* was correlated with the reduction of β-catenin and GATA-1 but not FOG-1 ([Fig. 4f](#F4){ref-type="fig"}).

Inhibition of 5-LO prolongs survival of CML mice {#S6}
------------------------------------------------

Zileuton treatment suppressed LSCs in CML mice ([Fig. 4](#F4){ref-type="fig"}). We examined whether 5-LO serves as a potential target in LSCs for treating CML. Mice with BCR-ABL-induced CML were treated with a placebo, the 5-LO inhibitor Zileuton, imatinib alone, or two agents in combination. All placebo-treated mice developed and died of CML within 4 weeks after the induction of CML by BCR-ABL. Zileuton inhibited *Alox5* function in CML mice, as plasma level of LTB4 was decreased compared to placebo-treated CML mice ([Fig. 5a](#F5){ref-type="fig"}). As expected, imatinib treatment was effective in treating CML, but Zileuton treatment was even more effective ([Fig. 5b](#F5){ref-type="fig"}). Treatment of CML mice with both Zileuton and imatinib had a better therapeutic effect than with either Zileuton or imatinib alone in prolonging survival of the mice ([Fig. 5b](#F5){ref-type="fig"}). Prolonged survival of Zileuton-treated CML mice correlated with less severe leukemia cell infiltration to the lungs and the spleens ([Fig. 5c](#F5){ref-type="fig"}). In peripheral blood of CML mice treated with Zileuton and imatinib, GFP^+^Gr-1^+^ leukemia cells gradually decreased with treatment, and dropped from over 50% to less than 2%, as analyzed at day 60 after the induction of CML ([Fig. 5d](#F5){ref-type="fig"}). Although these mice eventually died ([Fig. 5d](#F5){ref-type="fig"}), FACS analysis barely detected any GFP^+^Gr-1^+^ myeloid leukemic cells in peripheral blood at death (data not shown), indicating that myeloid leukemia was eliminated. Instead, these mice developed ALL, as shown by the presence of GFP^+^B220^+^ leukemic cells in peripheral blood (data not shown). Zileuton treatment did not have an inhibitory effect on normal myeloid cells (GFP^−^Gr-1^+^) in peripheral blood of the same animals, as the number of these non-leukemia cells increased during the treatment ([Fig. 5e](#F5){ref-type="fig"}). In bone marrow of Zileuton-treated CML mice, GFP^+^Gr-1^+^ myeloid leukemia cells also dropped to low levels during the treatment ([Fig. 5f](#F5){ref-type="fig"}). Prolonged survival of CML mice by Zileuton treatment is consistent with the inhibitory effect of Zileuton on LSCs ([Fig. 4b](#F4){ref-type="fig"}). Zileuton treatment caused a reduction of white blood cell counts less dramatically than did imatinib treatment ([Supplementary Fig. 8](#SD1){ref-type="supplementary-material"}), presumably because Zileuton targeted LSCs and imatinib inhibited more differentiated leukemic cells. Zileuton treatment also prolonged survival of mice with CML induced by BCR-ABL-T315I ([Supplementary Fig. 9](#SD1){ref-type="supplementary-material"}).

Elevation of LTB4 level was observed in bone marrow cells of CML patients [@R38]. However, a later report from the same group showed that the level of leukotriene C4 (LTC4) synthase, which is a key enzyme in the biosynthesis of LTC4 and represents a different metabolic pathway from LTB4, was elevated in human CML cells [@R39]. Therefore, we examined whether BCR-ABL stimulates LTC4 production in CML mice using an ELISA method. We did not observe an increase of plasma LTC4 levels in mice receiving BCR-ABL-expressing wild type bone marrow cells (BCR-ABL+Alox5^+/+^) as compared to mice receiving BCR-ABL-expressing *Alox5* deficient bone marrow cells (BCR-ABL+Alox5^−/−^). The mean level of LTC4 was 128.63 pg/ml for the *BCR-ABL*+*Alox5^+/+^* group and 154.84 pg/ml for the *BCR-ABL*+*Alox5^−/−^* group, respectively.

*Alox5* deficiency does not significantly affect normal HSCs {#S7}
------------------------------------------------------------

*Alox5* deficiency or inhibition of 5-LO by Zileuton specifically impaired the function of *Alox5^−/−^* LSCs but not non-BCR-ABL-expressing *Alox5^−/−^* HSCs in CML mice ([Fig. 4](#F4){ref-type="fig"}, [Fig. 5](#F5){ref-type="fig"}), showing that these *Alox5^−/−^* HSCs had stronger stem cell ability to engraft recipient mice than did *Alox5^−/−^* LSCs in the same animals. However, these results did not clearly show whether *Alox5* deficiency affected the function of normal HSCs. This question is important, because it is critical to know whether *Alox5* deficiency or inhibition of 5-LO lowers the function of HSCs below their normal level, especially if *Alox5* were considered as a therapeutic target. We characterized hematopoietic cell lineages in bone marrow and peripheral blood of *Alox5^−/−^* mice in comparison with those of wild type B6 mice. The percentages of HSCs (Lin^−^c-Kit^+^Sca-1^+^), LT-HSCs (Lin^−^c-Kit^+^Sca-1^+^CD34^−^), ST-HSCs (Lin^−^c-Kit^+^Sca-1^+^CD34^+^Flt3^−^) and MPPs (Lin^−^c-Kit^+^Sca-1^+^CD34^+^Flt3^+^) in bone marrow of *Alox5^−/−^* mice were only slightly lower than those of wild type mice ([Fig. 6a](#F6){ref-type="fig"}), and the percentages of Gr-1^+^, Mac-1^+^, B220^+^, or CD3E^+^ cell populations in bone marrow of these mice were similar to those of wild type mice ([Fig. 6b](#F6){ref-type="fig"}). In peripheral blood, the numbers of Gr-1^+^ and Mac-1^+^ cells in *Alox5^−/−^* mice were even higher than those in wild type mice ([Fig. 6b](#F6){ref-type="fig"}). These results demonstrated that *Alox5* deficiency did not lead to significant decrease in the numbers of hematopoietic cell lineages.

To compare the function of HSCs between *Alox5^−/−^* and wild type mice, we first performed engraftment assay, in which several doses of *Alox5^−/−^* or wild type bone marrow cells were transplanted into lethally irradiated wild type B6 mice. The engraftment ability of *Alox5^−/−^* bone marrow cells was slightly lower than that of wild type bone marrow cells, as 5×10^4^ wild type bone marrow cells completely protected death of lethally irradiated recipient mice, whereas the same number of *Alox5^−/−^* bone marrow cells partially rescued the irradiated mice ([Fig. 6c](#F6){ref-type="fig"}). The minor engraftment defect of *Alox5^−/−^* bone marrow cells was further examined in a competitive reconstitution analysis, in which *Alox5^−/−^* (CD45.2) and wild type (CD45.1) bone marrow cells were 1:1 mixed and then transferred into recipient mice. 12 weeks after the transplantation, the percentages of CD45.2 Gr-1^+^ and Mac-1^+^ cells were slightly lower than those of CD45.1 Gr-1^+^ and Mac-1^+^ cells in peripheral blood ([Fig. 6d](#F6){ref-type="fig"}), indicating that *Alox5^−/−^* HSCs had slightly lower stem cell function as compared to wild type HSCs. However, the effect of *Alox5* deficiency on normal HSCs is much less than that on LSCs, as the competitive engraftment capability of the sorted *Alox5^−/−^* LSCs was about thirty fold lower than that of wild type LSCs as assayed at day 25 after CML induction ([Fig. 3c](#F3){ref-type="fig"}), comparing to the one fold difference between *Alox5^−/−^* and normal HSCs ([Fig. 6d](#F6){ref-type="fig"}). This was further supported by the observation that *Alox5^−/−^* LSCs failed to induce CML ([Fig. 3c](#F3){ref-type="fig"}). We also compared the numbers of bone marrow CMP, GMP, MEP, and CLP between wild type and *Alox5^−/−^* mice, and no significant differences were found ([Fig. 6e](#F6){ref-type="fig"}), suggesting that there were no significant functional defects in these progenitor cells. The minor functional defect of *Alox5^−/−^* HSCs prompted us to examine whether there were any cellular changes in cell cycle and gene expression of β-catenin, GATA-1 and FOG-1 in these cells. We found that there were slightly higher percentages of both LT-HSCs and ST-HSCs/MPPs in the S+G2M phase of the cell cycle in *Alox5^−/−^* bone marrow cells than in wild type bone marrow cells ([Fig. 6f](#F6){ref-type="fig"}), in contrast to the only increase in LT-LSCs in S+G2M phase of the cell cycle in BCR-ABL-expressing *Alox5^−/−^* bone marrow cells ([Fig. 4d](#F4){ref-type="fig"}). This further indicates that there is no differentiation blockade in *Alox5^−/−^* HSCs and that *Alox5* deficiency has distinct biological effect on normal HSCs and LSCs. To support this idea, we compared the expressive levels of β-catenin, GATA-1 and FOG-1 in HSCs of wild type and *Alox5^−/−^* mice. We found that the minor functional defect of *Alox5^−/−^* HSCs was correlated with a decreased expression of GATA-1 and FOG-1, and that β-catenin expression was increased in *Alox5^−/−^* HSCs compared to that in wild type HSCs ([Fig. 6g](#F6){ref-type="fig"}). Different expression patterns of β-catenin, GATA-1 and FOG-1 in *Alox5^−/−^* HSCs ([Fig. 6g](#F6){ref-type="fig"}) and LSCs ([Fig. 4e](#F4){ref-type="fig"}) indicate that these three genes function differently in LSCs and normal HSCs.

*Alox5* is not required for the induction of lymphoid leukemia by BCR-ABL {#S8}
-------------------------------------------------------------------------

We tested whether *Alox5* plays a role in BCR-ABL-induced acute lymphoblastic leukemia (ALL), which originates from committed lymphoid progenitors [@R34]. We have previously shown that BCR-ABL-expressing pro-B cells serve as LSCs for this disease [@R23]. Wild type or *Alox5^−/−^* donor bone marrow cells were transduced by BCR-ABL retrovirus, followed by transplantation of the transduced cells into lethally irradiated wild type B6 recipient mice. Both groups of mice developed and died of ALL with similar disease latency and survival time ([Fig. 7a](#F7){ref-type="fig"}). FACS analysis of lymphoid leukemia cells showed that both group of ALL mice had similar percentages ([Fig. 7b](#F7){ref-type="fig"}) and numbers ([Fig. 7c](#F7){ref-type="fig"}) of B220^+^ leukemia cells in peripheral blood of these mice. Together these results showed that *Alox5* did not contribute to the development of ALL induced by BCR-ABL, and suggest that *Alox5* is not required by ALL stem cells, but is specifically required by CML stem cells. Consistent with these findings, BCR-ABL did not up-regulate *Alox5* function in ALL, as the plasma level of LTB4 in recipients of *BCR-ABL*-transduced wild type bone marrow cells was not significantly higher compared to recipients of *BCR-ABL*-transduced *Alox5^−/−^* bone marrow cells ([Fig. 7d](#F7){ref-type="fig"}).

Disccusion {#S9}
==========

The specific role of the *Alox5* gene in regulating the function of LSCs but not normal HSCs shows a new mechanism for how cancer and normal stem cells distinctly self-renew and differentiate, and provides a potential novel strategy for curative therapy of CML induced by BCR-ABL. Although *Alox5* and its related pathways were identified in LSCs of CML in this study, they may play a critical role in regulating LSCs of myeloid leukemias induced by other types of oncogenes. This idea is supported by our preliminary finding that the development of Tel-PDGFR-beta induced myeloid leukemia was also largely prevented in the absence of the *Alox5* gene (data not shown). In addition, similar phenomenon that a gene specifically regulates cancer stem cells but not normal stem cells may likely be found in other types of cancers.

The mechanism for the specific role of the *Alox5* gene in regulating function of LSCs but not normal HSCs remains to be further elucidated. We showed the differential regulation of the beta-catenin gene in wild type and *Alox5* deficient LSCs, partially explaining the specific inhibitory effect of *Alox5* deficiency on LSCs but not on normal HSCs. It is reasonable to think that these two types of stem cells utilize different pathways for self-renewal and differentiation, and *Alox5* represents a critical difference in these stem cells. It is likely that BCR-ABL stimulates transcription of *Alox5* to jointly form a unique pathway critical for LSC function. Because the transcriptional activation of *Alox5* by BCR-ABL is not inhibited by the BCR-ABL kinase inhibitor imatinib, this at least partially explains why imatinib does not inhibit LSCs in CML mice [@R23]. It is hopeful that targeting *Alox5* in combination with a BCR-ABL inhibitor that eliminates BCR-ABL protein, such as a heat shock protein 90 inhibitor [@R40], would lead to a better control of CML. 5-LO inhibitor and imatinib could also be a good combination, with one inhibiting LSCs and another eliminating differentiated leukemia cells.

We show that *Alox5* deficiency causes the depletion of LSCs in CML mice, and we believe that three biological changes (blockade of differentiation, asymmetric cell division and apoptosis) contribute to the eradication of these stem cells. At present, it is difficult to know which of the three biological changes plays a major role in depleting LSCs, and further mechanistic studies are required to answer this question.

No studies have shown a role of *Alox5* in regulation of LSCs. Our findings in this study first demonstrate that *Alox5* is a critical regulator of LSCs in CML, providing an *in vivo* system for investigating underlying molecular mechanisms. Human CML microarray studies have shown that *Alox5* is differentially expressed in CD34^+^ CML cells [@R41],[@R42], suggesting a role of *Alox5* in human CML stem cells. An *in vitro* study also supports the role of *Alox5* in CML, and in this study the treatment of CML blast cells in culture with 5-LO inhibitors reduced cell proliferation [@R43], although genetic approach is required to rule out any off-target effects. Our study shows complete eradication of myeloid leukemia in mice by removing and inhibiting 5-LO, prompting us to test this novel therapeutic strategy in human CML patients in the future. *Alox5* function has been linked to many important signaling pathways such as p53 [@R26], NF-kB [@R31], and PI3K [@R31]. PI3K is regulated by Pten, which plays a critical role in AML stem cells in mice [@R16]. Thus, inhibition of *Alox5* function may hold a promise for treating other types of malignant diseases. In addition, the impairment of LSCs in CML development by inhibiting *Alox5* function also suggests that *Alox5* may activate unknown pathways, and investigation of this *Alox5* network is critical to understanding the mechanisms by which LSCs survive, self-renew, and differentiate. Besides LSCs in CML, specific signaling networks are likely found in other cancer stem cells, relative to their normal stem cell counterparts.

Methods {#S10}
=======

Mice {#S11}
----

C57BL/6J--CD45.1, C57BL/6J--CD45.2, and homozygous *Alox5* knockout (*Alox5^−/−^*) mice in C57BL/6 background were obtained from The Jackson Laboratory. Mice were maintained in a temperature- and humidity-controlled environment and given unrestricted access to 6% chow diet and acidified water. *Alox5^−/−^* mice have normal hematopoietic cell counts in bone marrow and peripheral blood [@R27].

Flow cytometry and identification of leukemia and normal hematopoietic cell lineages {#S12}
------------------------------------------------------------------------------------

Hematopoietic cells were collected from bone marrow and peripheral blood of the normal and diseased mice, and red blood cells were lysed with NH~4~Cl red blood cell lysis buffer (pH 7.4). The cells were washed with PBS, and stained with B220-PE for B cells, Gr-1-APC for neutrophils, Mac-1-PE for macrophage, CD3E--APC for T cells, and Sca-1-PE-cy7/c-Kit-APC-cy7/CD34-APC/CD135 (Flt3)-PE for hematopoietic stem cells. After staining, the cells were washed once with PBS and subjected to FACS analysis.

Bone marrow transduction/transplantation {#S13}
----------------------------------------

The retroviral vector MSCV-IRES-eGFP carrying the p210 BCR-ABL cDNA and retroviral transduction and transplantation of mouse bone marrow cells for induction of CML and ALL by BCR-ABL had been described previously [@R40],[@R44].

Measurement of plasma LTB4 {#S14}
--------------------------

Plasma of BCR-ABL induced CML mice were collected on day 20 post induction of the disease, and stored at the −80 °C before use. An enzyme immunoassay was carried out to measure the LTB4 levels in plasma using an ELISA kit (Cayman Chemical, Ann Arbor, MI) following the manufacturer's instruction. Briefly, 50 ul of each standard or plasma sample was added to each well of 96-well plates, followed by adding 50 ul of LTB4 AchE trancer to each well. Then, 50 ul of LTB4 EIA antiserum was added to each well, and incubated the plates at 4 °C overnight. Next day, the plates were read and the results were analyzed.

Western blot analysis and antibodies {#S15}
------------------------------------

Antibodies against c-ABL, β-actin, and 5−LO were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Protein lysates were prepared by lysing cells in RIPA buffer, and Western blotting was carried out as described previously [@R45].

Real-time PCR {#S16}
-------------

Total mRNA was isolated from HSCs or LSCs isolated by the FACS sorting. cDNA was synthesized using the Ovation-Pico cDNA synthesis method. Real-time PCR (RT-PCR) was performed to detect expression of β-catenin, GATA-1 and FOG-1 with the primers shown in the [Supplementary Table 1](#SD1){ref-type="supplementary-material"}.

Drug treatment {#S17}
--------------

Zileuton (Critical Therapeutics. Inc) and Imatinib (Novartis) were dissolved in water. The drugs were given orally in a volume of less than 0.3 ml by gavage (300 mg/kg, twice a day for Zileuton, and 100 mg/kg, twice a day for Imatinib) beginning at 8 days after bone marrow transplantation, and continuing until the morbidity or death of the leukemia mice. Water was used as placebo.

Supplementary Material {#SM}
======================
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![*Alox5* is essential for the induction of CML induced by BCR-ABL\
**a**, Bone marrow cells from C57BL/6 mice (B6) were transduced with retrovirus containing BCR-ABL/GFP or GFP alone (BCR-ABL-IRES-GFP-pMSCV or IRES-GFP-pMSCV), and then transferred into B6 recipient mice to induce CML. One group of CML mice was treated with imatinib (150 mg/kg body weight/ per dose, once every 4 hours) for 5 doses beginning at day 13 post bone marrow transplantation (BMT). Bone marrow cells were isolated from CML mice, and were sorted by FACS for GFP^+^Lin^−^c-Kit^+^Sca-1^+^ cells (normal or CML stem cells). Total RNA was isolated from these sorted cells for DNA micorarray analysis. Expression of the *Alox5* gene was up-regulated by BCR-ABL in CML stem cells as compared to the sorted GFP^+^Lin^−^c-Kit^+^Sca-1^+^ cells that did not express BCR-ABL, and this up-regulation was not prevented by imatinib treatment. **b**, Bone marrow cells from C57BL/6 mice (B6) were transduced with retrovirus containing BCR-ABL/GFP or GFP alone to induce CML as described in **a**. Bone marrow cells were isolated from the mice were sorted by FACS for GFP^+^Lin^−^c-Kit^+^Sca-1^+^ cells, and then total RNA was isolated from these sorted cells for comparing *Alox5* expression between GFP vector-transduced normal stem cells and BCR-ABL-transduced LSCs by RT-PCR. Expression of the *Alox5* gene was significantly up-regulated by BCR-ABL in LSCs as compared to the sorted GFP vector-transduced normal stem cells (p\< 0.001). **c**, The plasma level of LTB4 in recipients of *BCR-ABL*-transduced bone marrow cells was significantly higher than that in recipients of bone marrow cells transduced with GFP-containing retrovirus (p\< 0.05), and this increased level of LTB4 was not observed in recipients of *Alox5^−/−^* bone marrow cells transduced by *BCR-ABL*. These results indicated that BCR-ABL up-regulates LTB4 through Alox5. **d**, Kaplan-Meier survival curves for recipients of *BCR-ABL*-transduced bone marrow cells from wild type or *Alox5^−/−^* donor mice (10 mice per group). All recipients of *BCR-ABL*-transduced bone marrow cells from wild type donor mice developed CML and died within 4 weeks after bone marrow transplantation (days post BMT), whereas recipients of *BCR-ABL*-transduced bone marrow cells from *Alox5^−/−^* donor mice survived. **e**, Gross appearance of the lungs and spleens showed severe lung hemorrhages and splenomegaly of recipients of BCR-ABL-transduced bone marrow cells from wild type but not *Alox5^−/−^* donor mice. **f**, Photomicrographs of haematoxylin and eosin-stained lung and spleen sections from recipients of *BCR-ABL*-transduced bone marrow cells from wild type or *Alox5^−/−^* donor mice. **g**, FACS analysis showed gradual disappearance of GFP^+^Gr-1^+^ cells in peripheral blood (PB) and bone marrow (BM) of recipients of *BCR-ABL*-transduced bone marrow cells from *Alox5^−/−^* but not wild type donor mice. **h**, In recipients of BCR-ABL-transduced bone marrow cells from *Alox5^−/−^* donor mice, GFP^+^Gr-1^+^ cells in PB gradually decreased with time, whereas the GFPGr-1^+^ cells that did not express BCR-ABL gradually increased, showing that *Alox5* deficiency significantly inhibited engraftment of BCR-ABL-expressing but not normal BM cells in the same animals. Mean percentage for each group (n=5) was shown.](nihms115650f1){#F1}

![*Alox5* transgene rescues defective CML phenotype\
**a**, The rescue construct (BCR-ABL-IRES-Alox5-pMSCV) was used to transfect 293T cells to test for expression of 5-LO with mock- or BCR-ABL-IRES-GFP-pMSCV-transfected cells as controls. BCR-ABL and 5-LO were detected by Western blotting using antibodies against Abl and 5-LO. 5-LO protein was detected in cells transfected with BCR-ABL-IRES-Alox5-pMSCV. **b**, Bone marrow cells from B6 mice were transduced with retrovirus containing IRES-GFP-pMSCV (empty vector) or BCR-ABL-IRES-Alox5-pMSCV, and then transferred into B6 recipient mice to induce CML. The plasma level of LTB4 in recipients of BCR-ABL-IRES-Alox5-pMSCV-transduced bone marrow cells was significantly higher than that in recipients of bone marrow cells transduced with empty vector-containing retrovirus (p\< 0.01), confirming that the BCR-ABL-IRES-Alox5-pMSCV construct induced LTB4 production in mice. **c**, Kaplan-Meier survival curves for recipients of BCR-ABL-IRES-Alox5-pMSCV-transduced bone marrow cells from wild type (n=10) or *Alox5^−/−^* (n=9) donor mice. All recipient mice died. **d**, FACS analysis showed appearance of GFP^+^Gr-1^+^ cells in peripheral blood of recipients of BCR-ABL-IRES-Alox5-pMSCV-transduced bone marrow cells from both wild type and *Alox5^−/−^* donor mice. **e**, Peripheral blood smears showed accumulation of neutrophils, indicating high white blood cell counts in these CML mice. **f**, Photomicrographs of haematoxylin and eosin-stained lung and spleen sections from recipients of BCR-ABL-IRES-Alox5-pMSCV-transduced bone marrow cells from wild type or *Alox5^−/−^* donor mice.](nihms115650f2){#F2}

![Loss of *Alox5* impairs the function of CML stem cell\
**a**, BCR-ABL-expressing (GFP^+^) and non-BCR-ABL-expressing (GFP) Lin^−^c-Kit^+^Sca-1^+^ cells (CML stem cells) in BM and the spleens (SPL) were analyzed by FACS in recipients of *BCR-ABL*-transduced BM cells from wild type or *Alox5^−/−^* donor mice (n=4 for each group at two time points after BMT). Total number of GFP^+^Lin^−^c-Kit^+^Sca-1^+^ cells for each mouse was calculated as percentage of GFP^+^Lin^−^c-Kit^+^Sca-1^+^ cells x total cell count for the cells from femurs and tabias. Loss of Alox5 caused significant reduction of CML stem cells in BM (p\< 0.05). **b**, Equal numbers of the sorted GFP^+^Lin^−^c-Kit^+^Sca-1^+^ cells from recipients of *BCR-ABL*-transduced bone marrow cells (5000 cells each) from wild type (CD45.1) or *Alox5^−/−^*(CD45.2) donor mice were mixed, followed by transplantation into lethally irradiated wild type mice. At days 14 and 25 after BMT, FACS analysis showed that the percentages of CD45.1^+^ cells were much higher than those of CD45.2^+^ cells. All these mice died of CML, presumably due to the development of CML from CD45.1^+^ cells. **c**, GFP^+^Lin^−^c-kit^+^Sca-1^+^ cells sorted by FACS from *BCR-ABL*-transduced BM cells from wild type or *Alox5^−/−^* mice were injected into lethally irradiated wild type recipient mice (15000 GFP^+^Lin^−^c-kit^+^Sca-1^+^ cells per recipient mouse). At day 14 after BMT, GFP^+^ Gr-1^+^ cells in peripheral blood of the mice were analyzed by FACS. *Alox5*-deficient GFP^+^Lin^−^c-kit^+^Sca-1^+^ poorly engrafted. The mice receiving the *Alox5*-deficient GFP^+^Lin^−^c-kit^+^Sca-1^+^ cells survived (n=4), whereas the mice receiving the wild type GFP^+^Lin^−^c-kit^+^Sca-1^+^ cells died of CML (n=2). **d**, FACS analysis indicated the percentages of BCR-ABL-expressing (GFP^+^) and non-BCR-ABL-expressing (GFP) CMP, GMP, and MEP cells in BM of recipients of BCR-ABL-transduced wild type or *Alox5^−/−^* donor BM cells (n=4). The results showed that loss of Alox5 caused depletion of BCR-ABL-expressing but not non-BCR-ABL-expressing CMP, GMP, and MEP cells in BM of the mice.](nihms115650f3){#F3}

![Loss of Alox5 function blocks differentiation of LT-LSCs\
**a**, Bone marrow cells were isolated from recipients of *BCR-ABL*-transduced bone marrow cells from wild type or *Alox5^−/−^* donor mice, and FACS analysis showed that the percentages and total numbers of LT-LSCs (GFP^+^Lin^−^c-Kit^+^Sca-1^+^CD34-) and ST-LSCs /BCR-ABL-expressing MPP cells (Lin^−^c-Kit^+^Sca-1^+^CD34^+^) in recipients of BCR-ABL-transduced *Alox5^−/−^* (middle and right panels) donor BM cells were much lower than those in recipients of BCR-ABL-transduced wild type (left panel) donor BM cells (n=4). In addition, LT-LSCs in recipients of BCR-ABL-transduced *Alox5^−/−^* donor BM cells relatively accumulated due to the blockade of differentiation, resulting in depletion of ST-LSCs /BCR-ABL-expressing MPP cells as assayed at day 90 post BMT. **b**, Recipients of *BCR-ABL*-transduced bone marrow cells from wild type donor mice were treated with Zileuton (300 mg/kg, twice a day) beginning at 8 days after BMT. At days 20 and 90 post BMT, FACS analysis showed the depletion of ST-LSCs /BCR-ABL-expressing MPP cells in Zileuton-treated CML mice, indicating a blockade of differentiation of LT-LSCs. In contrast, in the same animals the percentages and total numbers of ST-HSCs /MPP cells were higher than those of LT-LSCs, indicating that Zileuton treatment did not lead to a blockade of differentiation of normal LT-HSCs in Zileuton-treated CML mice. **c**, Mice receiving wild type donor BM cells transduced with MSCV-IRES-GFP retrovirus were treated with a placebo or Zileuton as described in **b**. At day 14 after BMT, the numbers of GFP^+^Lin^−^c-Kit^+^Sca-1^+^ cells in BM and the spleens (SPL) of placebo- and Zileuton-treated mice were compared. Zileuton treatment did not result in a reduction of normal HSCs in the mice. **d**, At day 14 after BMT, bone marrow cells were isolated from recipients of *BCR-ABL*-transduced bone marrow cells from wild type or *Alox5^−/−^* donor mice. The cells were stained with Hoechst Blue, and DNA contents, represented by the percentages of three LSC populations (total LSCs, LT-LSCs, and ST-LSCs+MPPs) in the S+G2M phase of the cell cycle, was examined by FACS. Mean percentage for each cell population (n=5) was shown. **e**, At day 14 after BMT, bone marrow cells were isolated from recipients of *BCR-ABL*-transduced bone marrow cells from wild type or *Alox5^−/−^* donor mice. The cells were stained with PI and Hoechst Blue, and the percentages of LSCs positive for PI and Hoechst Blue, representing apoptotic cells, were determined by F ACS. **f**, Bone marrow GFP^+^Lin^−^c-Kit^+^Sca-1^+^ cells were sorted by FACS from recipients of GFP vector- or *BCR-ABL*-transduced bone marrow cells from wild type or *Alox5^−/−^* donor mice for isolation of total RNA, and expression of β-catenin, GATA-1 and FOG were detected by RT-PCR. Each bar represents the mean value of three samples. BMCs: bone marrow cells.](nihms115650f4){#F4}

![Inhibition of Alox5 prolongs survival of CML mice\
**a**, Zileuton treatment resulted in a reduction of the plasma LTB4 level in CML mice. **b**, Kaplan-Meier survival curves for CML mice treated with a placebo, Zileuton alone, imatinib alone, or both Zileuton and imatinib in combination. Zileuton-treated CML mice were much healthier than placebo-treated CML mice, and inhibition of Alox5 by Zileuton significantly prolonged survival of CML mice. **c**, Photomicrographs of haematoxylin and eosin-stained lung and spleen sections from CML mice treated with a placebo or Zileuton. **d**, FACS analysis showed gradual disappearance of GFP^+^Gr-1^+^ cells in PB of CML mice treated with Zileuton. **e**, In CML mice treated with Zileuton, GFP^+^Gr-1^+^ cells in PB gradually decreased with time, whereas the GFP^−^Gr-1^+^ cells that did not express BCR-ABL gradually increased, showing that inhibition of Alox5 with Zileuton significantly inhibited engraftment of BCR-ABL-expressing but not normal BM cells in the same animals. **f**, FACS analysis showed gradual disappearance of GFP^+^Gr-1^+^ cells in BM of CML mice treated with Zileuton.](nihms115650f5){#F5}

![*Alox5* deficiency does not significantly affect normal HSCs\
**a**, Bone marrow cells from wild type and *Alox5^−/−^* mice were analyzed by FACS for the percentages of total HSCs (Lin^−^c-Kit^+^Sca-1^+^), LT-HSCs (Lin^−^c-Kit^+^Sca-1^+^CD34^−^), ST-HSCs (Lin^−^c-Kit^+^Sca-1^+^CD34^+^Flt3), and MPPs (Lin^−^c-Kit^+^Sca-1^+^CD34^+^Flt3^+^). **b**, Cells from bone marrow and peripheral blood of wild type and *Alox5^−/−^* mice were analyzed by FACS for the percentages of Gr-1^+^, Mac-1^+^, B220^+^, and CD3E^+^ cells. **c**, Three doses (1×10^5^, 5×10^4^, and 2.5×10^4^) of wild type or *Alox5^−/−^* BM cells were injected into lethally irradiated recipient mice. Survival curves showed that there was only a minor engraftment defect of BM in *Alox5^−/−^* mice. **d**, *Alox5^−/−^*(CD45.2) and wild type (CD45.1) BM cells were 1:1 mixed and then transferred into recipient mice (n=20). 12 weeks after BMT, FACS analysis was carried out to compare the percentages of wild type and *Alox5^−/−^*Gr-1^+^, Mac-1^+^, B220^+^, and CD3E^+^ cells in PB of recipient mice. **e**, BM cells from BM of wild type and *Alox5^−/−^* mice were analyzed by FACS for the numbers of CMPs, GMPs, MEP, and CLPs. **f**, Bone marrow cells were isolated from wild type or *Alox5^−/−^* mice, and stained with Hoechst Blue. DNA contents in total HSCs, LT-HSCs, and ST-HSCs+MPPs in the S+G2M phase of the cell cycle were examined by FACS. **g**, Bone marrow HSCs were sorted by FACS from wild type or *Alox5^−/−^* mice for isolation of total RNA, and expression of β-catenin, GATA-1 and FOG were detected by RT-PCR. Each bar represents the mean value of three samples.](nihms115650f6){#F6}

![*Alox5* is not required for the induction of lymphoid leukemia by *BCR-ABL*\
**a**, Kaplan-Meier survival curves for recipients of *BCR-ABL*-transduced bone marrow cells from wild type (n=6) or *Alox5^−/−^* (n=8) donor mice. Both groups of mice developed and died of ALL. **b**, At day 14 post BMT, FACS analysis showed no difference in the percentages of GFP^+^B220^+^ cells in PB of recipients of *BCR-ABL*-transduced bone marrow cells from wild type or *Alox5^−/−^* donor mice. **c**, FACS analysis showed similar numbers of GFP^+^B220^+^ cells in PB of recipients of *BCR-ABL*-transduced bone marrow cells from wild type or *Alox5^−/−^* donor mice. **d**, The plasma levels of LTB4 in recipients of *BCR-ABL*-transduced bone marrow cells from wild type or *Alox5^−/−^* donor mice were compared. Loss of *Alox5* did not result in a reduction of the plasma LTB4 level in ALL mice.](nihms115650f7){#F7}
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